For the Inventor, By the Inventor

Enter assignee name

Plan-les-Ouates, Switzerland

Obseva S.a.

USPTO Granted Patents = 11

CIPO Patents = 16

EPO Patents = 7

Trademarks = 9

Forward Citations = 27

Loading Chart...

Loading Chart...

16 inventors (with patents filed for the assignee):

Andre Chollet (7 out of 7 patents)

Oliver Pohl (5 out of 7 patents)

Catherine Jorand-LeBrun (2 out of 17 patents)

4. Matthias Schwarz (2 out of 35 patents)

5. André Chollet (2 out of 2 patents)

6. Ernest Loumaye (2 out of 12 patents)

7. Vincent Pomel (2 out of 22 patents)

8. Patrick Naxos Page (2 out of 26 patents)

9. Anna Quattropani (2 out of 58 patents)

10. Jean-Pierre Gotteland (2 out of 20 patents)

11. Catherine Jorand-Lebrun (23 patents)

12. Jean-Pierre Gotteland (2 patents)

13. Olivier Pohl (0 patent)

14. Olivier Pohl (0 patent)

15. Patrick Naxos Page (0 patent)

11 patents: Sort by Forward Citations

1. 11524003 - Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof (2022-12-13),

2. 11419851 - Oral formulations of pyrrolidine derivatives (2022-08-23),

3. 11312683 - Pyrrolidine derivatives as oxytocin/vasopressin via receptors antagonists (2022-04-26),

4. 10752583 - Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, and methods of using the same (2020-08-25),

5. 10604482 - Pyrrolidine derivatives as oxytocin/vasopressin via receptors antagonists (2020-03-31),

6. 10555934 - Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof (2020-02-11),

7. 10478420 - Oral formulations of pyrrolidine derivatives (2019-11-19),

8. 10047048 - Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists (2018-08-14),

9. 9962367 - Oral formulations of pyrrolidine derivatives (2018-05-08),

10. 9718772 - Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, and methods of using the same (2017-08-01),

11. 9670155 - Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists (2017-06-06),

ObsEva is a clinical-stage biopharmaceutical company focusing on the development and commercialization of treatments for women's reproductive health and pregnancy-related conditions. Their pipeline includes potential therapies for endometriosis, uterine fibroids, preterm labor, and improving embryo transfer success rates. With a strong emphasis on scientific research and innovation, ObsEva aims to address unmet medical needs and improve patient outcomes in women's health.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 2 2025

11 Patents

#8 in Plan-les-Ouates

#1,018 in Switzerland

#50,126 in the World

Plan-les-Ouates, Switzerland

Obseva S.a.

Forward Citations = 27

16 inventors:

Andre Chollet (7 out of 7 patents)

Oliver Pohl (5 out of 7 patents)

Catherine Jorand-LeBrun (2 out of 17 patents)

4. Matthias Schwarz (2 out of 35 patents)

5. André Chollet (2 out of 2 patents)

Please report any incorrect information to support@idiyas.com

Loading…